Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2019 2020 2021
Months
January August May June
Previous Archive
04 June 2020 | Story Lacea Loader

It has come to the attention of the University of the Free State (UFS) that false and inaccurate statements have been circulating on Twitter on 4 June 2020, claiming that its students were not equipped or supported to study remotely during the COVID-19 lockdown. The UFS believes that it is important to engage in dialogue to correct any misconceptions and inaccuracies that are at risk of being perpetuated.

Contrary to these reports, the UFS has invested much time and resources in the development and deployment of low-tech online and distance approaches to learning and teaching. Since March 2020, the university has undertaken extensive measures to support its students after classes were suspended and to ensure the continuation of the academic programme.

Statements on Twitter include a number of inaccuracies, which the university wants to correct:

• The Institutional Student Representative Council (ISRC) was not suspended by the Rector and Vice-Chancellor, Prof Francis Petersen. In fact, the university management regularly meets with the ISRC on matters of concern to them. Student representatives also serve on a number of institutional committees – both before and during the national lockdown.
• No deregistration of any students has taken place.
• Since the end of April 2020, structured and managed data was provided to students to obtain access to academic content as well as to the academic platforms for free. However, to access this free data, students need to download the GlobalProtect app – this was communicated numerously and explained to students.  The university’s ICT Services will provide video and technical guides to all students to assist them with downloading the app.
• As of June 2020, all allowances for which students qualify and which are approved by NSFAS, have been paid by the university.
• Although online learning provides a solution to continue with programme delivery, the university is deeply aware of the fact that access may be a barrier – especially during these extraordinary times.  To assist vulnerable students, a total of 3 500 laptops have been procured by the UFS, enabling the university to assist eligible students in accessing the online platforms, obtaining learning material, and engaging with lecturers. The university is in the process of distributing the laptops to students who qualify. The Department of Higher Education, Science and Innovation’s process to provide laptops to students is separate from the 3 500 laptops procured by the UFS.  

The UFS remains committed to supporting its students in response to COVID-19 and is looking forward to working as a community to prepare for the institution’s response to the new challenges of responsibly returning to campus life from June 2020 onward. As staff and students start returning to the institution in a phased approach this month, the UFS will continue to comply with all applicable governmental directives and health guidelines to ensure the safety, health, and well-being of its students and staff.

Released by:
Lacea Loader (Director: Communication and Marketing)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept